The benefit of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in type 1 and 2 diabetes patients with micro and macro albuminuria is well established [23,24], as these drugs reduce proteinuria and prevent progression of CKD [25,26]. Here, SLC5A2 is linked to chronic kidney disease.